Global Still’s Disease Treatment Market, by Treatment (Pain Management, Corticosteroids, Tocilizumab, Canakinumab, Anakinra, and Others), by Route of Administration (Injectable and Oral), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$1,539.4 million in 2020 and is expected to exhibit a CAGR of 4.49% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Still’s disease is a rare systemic inflammatory condition classified under polygenic autoinflammatory disorder. The condition is characterized by persistent high spiking fever, salmon colored skin rash, and arthralgia. Still’s disease is more commonly observed in infants, known as systemic-onset juvenile idiopathic arthritis (SOJIA) whereas, in adults, it is referred to as adult-onset Still’s disease (AOSD). However, there is no single diagnostic test available for Still’s disease. Diagnosis is typically done based on the observation of aforementioned symptoms. Also, the treatment option for this condition is selected based on the varying degree of symptoms.
Players in the market are focused on research & development, drug approvals, and launching them in the market, which is driving growth of the still’s disease treatment market. Moreover, companies are focused on partnerships and joint agreements for the development of novel therapies. For instance, in May 2019, Chugai Pharmaceutical Co., Ltd. received expanded drug approval for adult-onset Still's disease from the Ministry of Health Labor and Welfare in Japan for Actemra (tocilizumab). Actemra is used for Still’s disease treatment.
Similarly, in April 2018, Swedish Orphan Biovitrum AB received expanded approval from the European Commission (EC) for Kineret (anakinra), which is an interleukin-1 receptor antagonist for the treatment of Still’s Disease. Kineret was previously approved for rheumatoid arthritis treatment. This approval expanded indication of anakinra as well as addresses the significant unmet medical need among Still’s disease patient population. Such factors are expected to strongly support growth of the still’s disease treatment market.
Still’s Disease Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 outbreak has adversely affected the still’s disease treatment market growth. It has become difficult for the researchers to conduct researches during this COVID-19 pandemic. People with Still's disease are at more risk to get infected with the COVID-19 virus. Therefore, key players in this industry are focusing on developing strategies to help patients to remain agile during the global disruptions due to the pandemic crisis. Moreover, the government bodies of various countries are taking initiatives to deal with the current chaos.
Browse 26 Market Data Tables and 28 Figures spread through 140 Pages and in-depth TOC on Still’s Disease Treatment Market, By Treatment (Pain Management, Corticosteroids, Tocilizumab, Canakinumab, Anakinra, and Others), By Route of Administration (Injectable and Oral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Forecast to 2027"
To know the latest trends and insights related to global Still’s disease treatment market, click the link below:
The rise in funding for research & development to develop novel treatment and therapies is a major factor propelling growth of the global still’s disease treatment market. Moreover, the emergence of drugs for the complications related to adult-onset still’s disease treatment is another factor boosting the market growth. For instance, in June 2020, the U.S. Food and Drug Administration (FDA) approved the usage of Canakinumab (Ilaris) in active still’s disease.
Key Takeaways of the Global Still’s Disease Treatment Market: